Anti B-cell maturation antigen CAR T-cell and antibody drug conjugate therapy for heavily pre-treated relapsed and refractory multiple myeloma: final policy recommendations

Anti B-cell maturation antigen CAR T-cell and antibody drug conjugate therapy for heavily pre-treated relapsed and refractory multiple myeloma: final policy recommendations

Collection:
Health Policy and Services Research
Contributor(s):
Institute for Clinical and Economic Review, issuing body.
Publication:
[Boston, Massachusetts] : Institute for Clinical and Economic Review, May 11, 2021
Language(s):
English
Format:
Text
Subject(s):
Immunoconjugates
Immunotherapy, Adoptive
Multiple Myeloma
United States
Genre(s):
Technical Report
Abstract:
The following policy recommendations reflect the main themes and points made during the Policy Roundtable discussion at the April 16, 2021 Midwest CEPAC public meeting on the use of anti-BCMA therapies for the treatment of heavily pre-treated multiple myeloma. At the meeting, ICER presented the findings of its revised report on these treatments and the Midwest CEPAC voting council deliberated on key questions related to their comparative clinical effectiveness, potential other benefits and contextual considerations, and long-term value for money at current prices. Following the votes, ICER convened a Policy Roundtable of two patients, two clinical experts, two payers, and one representative from a pharmaceutical manufacturer to discuss how best to apply the evidence and votes to real-world practice and policy. The discussion reflected multiple perspectives and opinions, and therefore, none of the statements below should be taken as a consensus view held by all participants.
Copyright:
Reproduced with permission of the copyright holder. Further use of the material is subject to CC BY license. (More information)
Extent:
1 online resource (1 PDF file (12 pages))
NLM Unique ID:
9918401083806676 (See catalog record)
Permanent Link:
http://resource.nlm.nih.gov/9918401083806676